Kyowa Hakko Kirin Co. Ltd. secured exclusive rights to develop and commercialize Ardelyx Inc.'s tenapanor for the treatment of heart and kidney diseases in Japan.
Ardelyx will receive $30 million up front and is eligible to receive additional development and commercialization milestones worth up to $130 million, along with high-teen royalties throughout the term of the agreement.
Tenapanor is in phase 3 development in the U.S. for the treatment of hyperphosphatemia, abnormally elevated phosphate levels in the blood, in patients with end-stage renal disease who are on dialysis.
